Tag

Action Radiotherapy believes that every cancer patient in the UK should have access to the best radiotherapy treatment available.

We aim to support radiotherapy research and development and support radiotherapy professionals by providing online tools to enhance collaboration.

Radiotherapy is effective and inexpensive compared with some cancer treatments and second only to surgery in its potential to cure cancer. Even small improvements in how radiotherapy is delivered could lead to large increases in the number of patients cured, and improve palliative treatment for others

Action Radiotherapy was launched in the House of Lords in July 2010. It grew out of the Academic Clinical Oncology and Radiobiology Research Network (ACORRN) which was launched initially by the National Cancer Research Institute in 2005 to harness the power of the radiation research base in the UK.

Action Radiotherapy receives no government or other funding and its activities are entirely dependent on charitable donations.

Dr Rohini Sharma is dual accredited in both medical oncology and clinical pharmacology and is a consultant based at the Hammersmith Hospital.

She completed her medical training at the University of Adelaide, and undertook her specialist oncology training at the Royal Prince Alfred Hospital, Sydney and her clinical pharmacology training at Westmead Hospital, Sydney.

Rohini was awarded an NHMRC PhD Fellowship at the Westmead Millennium Institute, University of Sydney. She was awarded a HEFCE Clinical Senior Lecturer position in May 2010. Rohini's clinical interests are in gastrointestinal malignancies and early phase clinical trials. Her research interests are in PET imaging within the Comprehensive Cancer Imaging Center .

Professor Sikora is a British physician specialising in oncology. He is medical director of Rutherford Health, and Director of Medical Oncology at the Bahamas Cancer Centre. He is also Professor of Medicine at the University of Buckingham, and a partner in and dean of Buckingham's medical school.

Professor Sikora studied medical science and biochemistry at Cambridge, where he obtained a double first.

After clinical training he became a house physician at The Middlesex Hospital and registrar in oncology at St Bartholomew’s Hospital. He later became a research student at the MRC Laboratory for Molecular Biology in Cambridge working with Nobel Prize winner, Dr Sydney Brenner.

He obtained his PhD and became a clinical fellow at Stanford University, California before returning to direct the Ludwig Institute in Cambridge.

He has been Clinical Director for Cancer Services at Hammersmith for 12 years and established a major cancer research laboratory there funded by the Imperial Cancer Research Fund. He chaired Help Hammer Cancer, an appeal that raised £8m towards the construction of the new Cancer Centre at Hammersmith. He became Deputy Director (Clinical Research) of the ICRF.From 1997 to 1999 he was Chief of the WHO Cancer Program and from 1999 to 2002 and Vice President, Global Clinical Research (Oncology) at Pharmacia Corporation.

He has published over 300 papers and written or edited 20 books and is on the editorial board of several journals and is the founding editor of Gene Therapy and Cancer Strategy.

He was a member of the UK Health Department’s Expert Advisory Group on Cancer (the Calman-Hine Committee), the Committee on Safety of Medicines and remains an adviser to the WHO. He currently directs a cancer drug donation programme in Africa.